CORRECTING and REPLACING GRAPHIC Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the ASCO 2019 Annual Meeting
Puma Biotechnology, Inc. - Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2019 San Antonio Breast Cancer
PUMA RS-X Reinvention Red Blast 2019 for Sale | Authenticity Guaranteed | eBay
PUMA published its first quarter 2019 results - PUMA CATch up
Puma Energy announces Q1 2019 results
PUMA® - PUMA posts record sales and EBIT as strong growth momentum continues throughout 2019
Puma launches self-lacing Puma Fi trainers
PUMA® - PUMA Investor Relations
PUMA® - PUMA DELIVERS STRONG GROWTH IN SALES AND PROFITABILITY IN 2018